PRXL2A Antibody

What is PRXL2A and why is it important in research?

PRXL2A (Peroxiredoxin-like 2A) is an antioxidant protein that protects cells from oxidative stress and participates in redox regulation. The human canonical protein consists of 229 amino acid residues with a molecular weight of 25.8 kDa . It has gained research significance due to its potential role in cancer progression, particularly in oral squamous cell carcinoma (OSCC) and endometrial cancer, where higher expression correlates with poorer patient outcomes . PRXL2A's function in oxidative stress management makes it relevant for studying cellular protection mechanisms and potential therapeutic targeting.

What are the most validated applications for PRXL2A antibodies?

PRXL2A antibodies have been successfully validated for several research applications, with Western Blot (WB) and ELISA being the most consistently reliable across different commercial sources . Immunocytochemistry (ICC) and immunohistochemistry (IHC) applications are also supported by some antibody products but may require additional optimization . When selecting an antibody, researchers should prioritize those validated specifically for their intended application and target species to ensure reliable results.

Which biological samples are most appropriate for PRXL2A detection?

PRXL2A is expressed in the cytoplasm and is also secreted, making it detectable in various sample types . The protein is notably expressed in CSF1 and TNFSF11-stimulated CD14+ peripheral blood mononuclear cells (PBMCs) . For cancer research, tumor tissues show significantly higher PRXL2A expression compared to matched non-cancerous tissues, particularly in OSCC and endometrial cancer models . Cell lines commonly used for PRXL2A studies include SAS (oral cancer), Ishikawa, and AN3CA (endometrial cancer) cells .

How should I optimize antibody dilution for Western blot detection of PRXL2A?

For optimal Western blot detection of PRXL2A, begin with a titration experiment using the manufacturer's recommended dilution range (typically 1:500 to 1:2000). Given PRXL2A's molecular weight of 25.8 kDa, use appropriate percentage SDS-PAGE gels (12-15%) for optimal resolution . Include positive controls (cell lines known to express PRXL2A such as stimulated PBMCs) and negative controls (knockdown samples if available). For quantitative analysis, normalize PRXL2A expression to a stable housekeeping protein like GAPDH . Multiple technical replicates are recommended to ensure reproducibility of results.

How can I address cross-reactivity issues when working with PRXL2A antibodies?

Cross-reactivity can be a significant concern with PRXL2A antibodies due to sequence homology with other peroxiredoxin family members. To address this:

• Select antibodies raised against unique epitopes of PRXL2A that minimize overlap with related proteins

• Always validate antibody specificity using positive and negative controls

• Consider using multiple antibodies targeting different PRXL2A epitopes to confirm results

• Include PRXL2A knockdown or knockout samples as negative controls

• For cross-species studies, verify sequence conservation at the epitope region

If persistent cross-reactivity issues occur, pre-absorption with recombinant related proteins or using monoclonal antibodies with higher specificity may be necessary.

What are the best protein extraction methods for detecting PRXL2A in cellular compartments?

Since PRXL2A is found in both cytoplasmic and secreted fractions, differential extraction methods are recommended:

For cellular PRXL2A:

• Use mild lysis buffers (RIPA or NP-40 based) with protease inhibitors

• Include antioxidants (e.g., DTT or β-mercaptoethanol) to preserve redox-sensitive proteins

• Perform fractionation to separately analyze cytoplasmic and membrane-associated pools

For secreted PRXL2A:

• Collect serum-free conditioned media after 24-48 hours of culture

• Concentrate proteins using TCA precipitation or centrifugal filters

• Consider immunoprecipitation for enrichment before Western blotting

Quantification methods like BCA protein assay should be used to normalize loading volumes for consistent results .

How can I optimize immunohistochemical detection of PRXL2A in tissue samples?

For successful IHC detection of PRXL2A in tissue samples:

• Antigen retrieval: Test both heat-induced epitope retrieval (citrate buffer, pH 6.0) and enzymatic methods to determine optimal conditions

• Blocking: Use 5-10% normal serum from the same species as the secondary antibody to reduce background

• Primary antibody: Incubate at 4°C overnight using validated antibodies for IHC applications

• Detection system: Polymer-based detection systems often provide better signal-to-noise ratio than avidin-biotin methods

• Controls: Include known positive tissues (e.g., OSCC samples) and negative controls (omitting primary antibody)

Optimization may require testing multiple antibody dilutions and antigen retrieval protocols to achieve specific staining with minimal background.

How can PRXL2A antibodies be employed in cancer research models?

PRXL2A antibodies have proven valuable in cancer research through multiple applications:

• Expression profiling: Western blot and IHC analyses have revealed PRXL2A overexpression in OSCC and endometrial cancer tissues compared to normal controls .

• Functional studies: Following PRXL2A knockdown, antibodies can verify protein reduction before assessing phenotypic changes in proliferation and colony formation assays, as demonstrated in endometrial cancer cell lines where PRXL2A knockdown significantly inhibited growth .

• Xenograft models: PRXL2A antibodies help validate protein expression in tumor tissues from xenograft studies, such as those using AN3CA cells with PRXL2A knockout that showed reduced tumor growth .

• Mechanism investigation: Antibodies facilitate the study of PRXL2A's interaction with regulatory pathways, including its targeting by miR-125b in oral cancer models .

These approaches collectively contribute to understanding PRXL2A's role in cancer progression and its potential as a therapeutic target.

What methodological approaches can be used to study PRXL2A's role in redox regulation?

To investigate PRXL2A's function in redox regulation, researchers can employ several complementary approaches:

• Oxidative stress assays: Measure ROS levels using fluorescent probes (DCFDA) in cells with modulated PRXL2A expression

• Protein oxidation state analysis:

  • Use non-reducing gel electrophoresis to preserve disulfide bonds

  • Apply redox proteomic approaches with differential alkylation of thiols

  • Employ mass spectrometry to identify specific oxidation sites

• Antioxidant capacity assessment:

  • Measure total antioxidant capacity in cells with varying PRXL2A levels

  • Quantify specific antioxidant enzyme activities (catalase, SOD, etc.)

• Stress resistance experiments:

  • Challenge cells with oxidative stressors (H₂O₂, paraquat)

  • Assess cell viability and damage markers in PRXL2A-normal vs. PRXL2A-deficient conditions

These methods can reveal PRXL2A's specific contribution to redox homeostasis and stress protection mechanisms.

What is the relationship between PRXL2A and microRNA regulation, and how can it be studied?

Research has identified miR-125b as a regulator of PRXL2A expression in oral cancer contexts . To investigate microRNA-PRXL2A interactions:

• Prediction and validation:

  • Use bioinformatic tools (e.g., miRWalk) to predict miRNA binding sites in PRXL2A's 3'UTR

  • Construct luciferase reporters containing wild-type and mutant PRXL2A 3'UTR sequences

  • Perform reporter assays to validate direct interaction between miRNAs and target sequences

• Expression correlation studies:

  • Quantify PRXL2A protein levels by Western blot and miRNA levels by qRT-PCR

  • Analyze inverse correlation patterns in tissue samples and cell lines

• Functional rescue experiments:

  • Express PRXL2A coding sequence without its 3'UTR to create a miRNA-resistant construct

  • Test whether this construct rescues phenotypes induced by miRNA overexpression

These approaches provide mechanistic insights into post-transcriptional regulation of PRXL2A and potential therapeutic targeting through miRNA pathways.

How should results from PRXL2A antibody-based experiments be quantified and analyzed?

For robust quantification and analysis of PRXL2A expression:

• Western blot quantification:

  • Use densitometry software (ImageJ, Image Lab) to measure band intensities

  • Normalize PRXL2A signals to housekeeping proteins (GAPDH, β-actin)

  • Present data as fold change relative to control samples

  • Perform statistical analysis across biological replicates (minimum n=3)

• IHC scoring systems:

  • Employ semi-quantitative scoring combining staining intensity (0-3) and percentage of positive cells

  • Consider automated image analysis for objective quantification

  • Have multiple pathologists score samples independently to ensure reproducibility

• qRT-PCR analysis:

  • Use the 2^-ΔΔCt method to calculate relative PRXL2A mRNA expression

  • Select appropriate reference genes validated for stability in your experimental system

Statistical approaches should include appropriate tests based on data distribution, with clear reporting of p-values and confidence intervals.

How can PRXL2A antibodies be used in combination with other techniques to study protein-protein interactions?

To investigate PRXL2A protein-protein interactions, combine antibody-based methods with complementary techniques:

• Co-immunoprecipitation (Co-IP):

  • Use PRXL2A antibodies to pull down protein complexes

  • Identify interacting partners by Western blot or mass spectrometry

  • Confirm specificity with appropriate controls (IgG, reverse Co-IP)

• Proximity ligation assay (PLA):

  • Detect in situ protein interactions with spatial resolution

  • Requires PRXL2A antibodies raised in different species from antibodies against potential interacting partners

• Bimolecular fluorescence complementation (BiFC):

  • Complement with genetic approaches to validate interactions

  • Express PRXL2A fused to partial fluorescent protein fragments

  • Use antibodies to confirm expression levels of fusion proteins

• FRET/FLIM analysis:

  • Study dynamic interactions in living cells

  • Use antibodies for validation of fusion protein expression

These multi-technique approaches provide stronger evidence for physiologically relevant protein-protein interactions involving PRXL2A.

What considerations are important when using PRXL2A antibodies in prognostic biomarker studies?

When evaluating PRXL2A as a potential prognostic biomarker:

• Antibody validation requirements:

  • Rigorous specificity testing is essential for clinical biomarker applications

  • Multiple antibody clones should show concordant results

  • Include appropriate positive and negative tissue controls

• Patient cohort considerations:

  • Ensure sufficient sample size with adequate statistical power

  • Include comprehensive clinical data and long-term follow-up

  • Account for potential confounding factors and heterogeneity

• Scoring and cutoff determination:

  • Establish standardized scoring protocols with minimal inter-observer variability

  • Define optimal cutoff values through ROC curve analysis or similar approaches

  • Validate cutoffs in independent patient cohorts

• Integration with other biomarkers:

  • Consider PRXL2A in multi-gene panels (e.g., with CDC25B, GNG3, ITIH3, and SDHB in endometrial cancer)

  • Use appropriate multivariate models to assess independent prognostic value

Research indicates PRXL2A overexpression correlates with worse survival in OSCC and is part of a prognostic signature in endometrial cancer, highlighting its potential clinical value.

What are the most effective approaches for PRXL2A knockdown or knockout experiments?

For manipulating PRXL2A expression levels in functional studies:

• siRNA-mediated knockdown:

  • Design multiple siRNA sequences targeting different regions of PRXL2A mRNA

  • Optimize transfection conditions for each cell type

  • Verify knockdown efficiency by Western blot and qRT-PCR

  • Assess transient effects 48-72 hours post-transfection

• shRNA-mediated stable knockdown:

  • Use lentiviral or retroviral delivery systems for long-term studies

  • Select transduced cells with appropriate antibiotics

  • Establish and validate stable cell lines before functional assays

  • Useful for in vivo xenograft studies

• CRISPR-Cas9 knockout:

  • Design guide RNAs targeting early exons of PRXL2A

  • Screen and isolate clonal populations

  • Confirm complete knockout by sequencing and Western blot

  • Consider potential compensation by related family members

• Rescue experiments:

  • Re-express PRXL2A in knockout cells to confirm specificity

  • Use antibodies to verify appropriate expression levels

Studies have demonstrated successful PRXL2A knockdown in cancer cell lines with significant effects on proliferation and colony formation.

How can researchers design experiments to investigate PRXL2A's role in specific cancer types?

To investigate PRXL2A's role in cancer:

• Expression profiling across cancer types:

  • Screen multiple cancer and matched normal tissues using validated antibodies

  • Compare PRXL2A expression with clinical parameters (stage, grade, survival)

  • Identify cancer types with significant PRXL2A dysregulation

• Functional assays after PRXL2A modulation:

  • Proliferation assays (MTT, BrdU incorporation)

  • Colony formation and soft agar growth

  • Migration and invasion assays

  • Apoptosis assessment (Annexin V, caspase activation)

• Mechanism investigation:

  • Examine effects on redox status in cancer cells

  • Assess impact on known oncogenic pathways

  • Investigate response to therapy (radiation, chemotherapy)

• In vivo models:

  • Xenograft studies with PRXL2A-modulated cells

  • Patient-derived xenografts with PRXL2A characterization

  • Correlation of tumor growth with PRXL2A expression

Research has shown PRXL2A knockdown inhibits proliferation and colony formation in endometrial cancer cells and reduces xenograft tumor growth, suggesting its oncogenic potential.